116 related articles for article (PubMed ID: 10623697)
1. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival.
Mackay HJ; Cameron D; Rahilly M; Mackean MJ; Paul J; Kaye SB; Brown R
J Clin Oncol; 2000 Jan; 18(1):87-93. PubMed ID: 10623697
[TBL] [Abstract][Full Text] [Related]
2. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
[TBL] [Abstract][Full Text] [Related]
3. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
4. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.
Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L
Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
7. Tumor buds show reduced expression of laminin-5 gamma 2 chain in DNA mismatch repair deficient colorectal cancer.
Shinto E; Baker K; Tsuda H; Mochizuki H; Ueno H; Matsubara O; Foulkes WD; Jass JR
Dis Colon Rectum; 2006 Aug; 49(8):1193-202. PubMed ID: 16773493
[TBL] [Abstract][Full Text] [Related]
8. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
9. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
11. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.
Andachi H; Yashima K; Koda M; Kawaguchi K; Kitamura A; Hosoda A; Kishimoto Y; Shiota G; Ito H; Makino M; Kaibara N; Kawasaki H; Murawaki Y
Br J Cancer; 2002 Aug; 87(4):441-5. PubMed ID: 12177781
[TBL] [Abstract][Full Text] [Related]
12. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
15. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix.
Giarnieri E; Mancini R; Pisani T; Alderisio M; Vecchione A
Clin Cancer Res; 2000 Sep; 6(9):3600-6. PubMed ID: 10999751
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
19. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Yndestad S; Austreid E; Knappskog S; Chrisanthar R; Lilleng PK; Lønning PE; Eikesdal HP
Breast Cancer Res Treat; 2017 May; 163(1):177-190. PubMed ID: 28213783
[TBL] [Abstract][Full Text] [Related]
20. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
